Bicycle Therapeutics PLC
NASDAQ:BCYC

Watchlist Manager
Bicycle Therapeutics PLC Logo
Bicycle Therapeutics PLC
NASDAQ:BCYC
Watchlist
Price: 20.6475 USD 1.91% Market Closed
Market Cap: 1.4B USD
Have any thoughts about
Bicycle Therapeutics PLC?
Write Note

Relative Value

The Relative Value of one BCYC stock under the Base Case scenario is 10.8117 USD. Compared to the current market price of 20.6475 USD, Bicycle Therapeutics PLC is Overvalued by 48%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BCYC Relative Value
Base Case
10.8117 USD
Overvaluation 48%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
39
vs Industry
25
Median 3Y
42.5
Median 5Y
41.1
Industry
7.7
Forward
37.1
vs History
vs Industry
Median 3Y
-7.7
Median 5Y
-7.7
Industry
22.7
Forward
-6.6
vs History
vs Industry
Median 3Y
-13
Median 5Y
-14.2
Industry
21.6
vs History
vs Industry
Median 3Y
-11.6
Median 5Y
-11.8
Industry
25.2
vs History
82
vs Industry
20
Median 3Y
2.6
Median 5Y
3
Industry
2.5
vs History
61
vs Industry
24
Median 3Y
22.1
Median 5Y
23
Industry
7.7
Forward
13.9
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9
vs History
vs Industry
31
Median 3Y
-3.6
Median 5Y
-4.2
Industry
4.2
Forward
-2.8
vs History
vs Industry
30
Median 3Y
-3.4
Median 5Y
-4.1
Industry
4.1
Forward
-2.7
vs History
vs Industry
31
Median 3Y
-7.1
Median 5Y
-9.7
Industry
5.7
vs History
vs Industry
28
Median 3Y
-6.1
Median 5Y
-8
Industry
3.6
vs History
57
vs Industry
18
Median 3Y
6.8
Median 5Y
8.6
Industry
4.6

Multiples Across Competitors

BCYC Competitors Multiples
Bicycle Therapeutics PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
Bicycle Therapeutics PLC
NASDAQ:BCYC
1.4B USD 38.6 -8.6 -2.8 -2.7
FR
Pharnext SCA
OTC:PNEXF
6T USD 37 888 840.5 -180 080 -218 674.5 -216 179.2
US
Abbvie Inc
NYSE:ABBV
314.7B USD 5.7 61.9 15.4 23.7
US
Amgen Inc
NASDAQ:AMGN
157B USD 4.8 37.1 17.4 32.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD 10.9 -241.6 24 25.2
US
Gilead Sciences Inc
NASDAQ:GILD
112.2B USD 4 890.3 9.9 9.9
US
Epizyme Inc
F:EPE
94.1B EUR 1 859.4 -474.5 -516.7 -502.9
AU
CSL Ltd
ASX:CSL
133.6B AUD 5.9 32.9 20.3 25.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD 6 17.8 16.2 18
US
Seagen Inc
F:SGT
39.3B EUR 17.9 -54.9 -59 -53.2
NL
argenx SE
XBRU:ARGX
34.5B EUR 18.6 -130.6 -105.1 -76.6
P/E Multiple
Earnings Growth
UK
Bicycle Therapeutics PLC
NASDAQ:BCYC
Average P/E: 208
Negative Multiple: -8.6
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -180 080 N/A
US
Abbvie Inc
NYSE:ABBV
61.9
412%
US
Amgen Inc
NASDAQ:AMGN
37.1
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -241.6
42%
US
Gilead Sciences Inc
NASDAQ:GILD
890.3
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -474.5 N/A
AU
CSL Ltd
ASX:CSL
32.9
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.9 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -130.6 N/A
EV/EBITDA Multiple
EBITDA Growth
UK
Bicycle Therapeutics PLC
NASDAQ:BCYC
Average EV/EBITDA: 17.2
Negative Multiple: -2.8
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -218 674.5 N/A
US
Abbvie Inc
NYSE:ABBV
15.4
28%
US
Amgen Inc
NASDAQ:AMGN
17.4
63%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
38%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
12%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -516.7 N/A
AU
CSL Ltd
ASX:CSL
20.3
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.2
46%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -105.1 N/A
EV/EBIT Multiple
EBIT Growth
UK
Bicycle Therapeutics PLC
NASDAQ:BCYC
Average EV/EBIT: 22.5
Negative Multiple: -2.7
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 179.2 N/A
US
Abbvie Inc
NYSE:ABBV
23.7
88%
US
Amgen Inc
NASDAQ:AMGN
32.9
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.2
44%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -502.9 N/A
AU
CSL Ltd
ASX:CSL
25.3
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53.2 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.6 N/A

See Also

Discover More
Back to Top